David A. Siegel Oramed Pharmaceuticals Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 263,500 shares of ORMP stock, worth $574,430. This represents 0.0% of its overall portfolio holdings.

Number of Shares

263,500

Previous 283,600 7.09%

Holding current value

$574,430

Previous $655,000 17.4%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.18 - $3.58 $43,818 - $71,958	-20,100 Reduced 7.09%	263,500 $769,000
Q4 2023 Feb 14, 2024	BUY	$1.71 - $2.57 $201,780 - $303,260	118,000 Added 71.26%	283,600 $655,000
Q3 2023 Nov 14, 2023	SELL	$2.51 - $3.55 $62,749 - $88,750	-25,000 Reduced 13.12%	165,600 $432,000
Q2 2023 Aug 14, 2023	SELL	$2.12 - $4.47 $539,116 - $1.14 Million	-254,300 Reduced 57.16%	190,600 $682,000
Q1 2023 May 15, 2023	BUY	$1.93 - $13.1 $372,490 - $2.53 Million	193,000 Added 76.62%	444,900 $969,000

Q4 2022 Feb 14, 2023	SELL	$6.21 - $12.03 $494,316 - $957,588	-79,600 Reduced 24.01%	251,900 $3.03 Million
Q3 2022 Nov 14, 2022	SELL	$4.6 - $9.91 $1.61 Million - $3.47 Million	-350,300 Reduced 51.38%	331,500 $2.15 Million
Q2 2022 Aug 15, 2022	BUY	$3.72 - $9.0 $73,656 - $178,200	19,800 Added 2.99%	681,800 $3.12 Million
Q1 2022 May 16, 2022	BUY	$8.19 - $13.89 $3.56 Million - $6.04 Million	434,700 Added 191.25%	662,000 $5.73 Million
Q4 2021 Feb 14, 2022	BUY	$12.98 - $29.75 $2.95 Million - $6.76 Million	227,300 New	227,300 $3.25 Million

Others Institutions Holding ORMP

# of Institutions

Shares Held

5.69M

Call Options Held

8.3K

Put Options Held

2.7K

View Full List

About ORAMED PHARMACEUTICALS INC.

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $84.6M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

More about ORMP

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account